FI62281C - Foerfarande foer framstaellning av antidepressivt verksamma 4-minoamfetaminderivat - Google Patents
Foerfarande foer framstaellning av antidepressivt verksamma 4-minoamfetaminderivat Download PDFInfo
- Publication number
- FI62281C FI62281C FI2576/74A FI257674A FI62281C FI 62281 C FI62281 C FI 62281C FI 2576/74 A FI2576/74 A FI 2576/74A FI 257674 A FI257674 A FI 257674A FI 62281 C FI62281 C FI 62281C
- Authority
- FI
- Finland
- Prior art keywords
- ether
- mixture
- solution
- yield
- dimethyl
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 122
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 78
- 239000000243 solution Substances 0.000 description 67
- 239000000203 mixture Substances 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 150000001875 compounds Chemical class 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- 238000000034 method Methods 0.000 description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 24
- 239000000460 chlorine Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- -1 lithium aluminum hydride Chemical compound 0.000 description 22
- 238000003756 stirring Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 16
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 239000012280 lithium aluminium hydride Substances 0.000 description 14
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 13
- 229940025084 amphetamine Drugs 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 10
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 10
- 239000005695 Ammonium acetate Substances 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 125000001931 aliphatic group Chemical group 0.000 description 10
- 229940043376 ammonium acetate Drugs 0.000 description 10
- 235000019257 ammonium acetate Nutrition 0.000 description 10
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000001430 anti-depressive effect Effects 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 8
- 229940005513 antidepressants Drugs 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 150000002170 ethers Chemical class 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000013256 coordination polymer Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- UXAZIFYAGDKABZ-UHFFFAOYSA-N 4-(2-aminopropyl)aniline Chemical class CC(N)CC1=CC=C(N)C=C1 UXAZIFYAGDKABZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000037023 motor activity Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940072690 valium Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- JVMSKGOQBHOVAB-UHFFFAOYSA-N n,n,3-trimethyl-4-(2-nitroprop-1-enyl)aniline Chemical compound CN(C)C1=CC=C(C=C(C)[N+]([O-])=O)C(C)=C1 JVMSKGOQBHOVAB-UHFFFAOYSA-N 0.000 description 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- TVJDQAJNZZLLOS-UHFFFAOYSA-N 1-(1-methyl-3,4-dihydro-2h-quinolin-6-yl)propan-2-amine;dihydrochloride Chemical compound Cl.Cl.CN1CCCC2=CC(CC(N)C)=CC=C21 TVJDQAJNZZLLOS-UHFFFAOYSA-N 0.000 description 4
- XPXZIZIGEKZVMQ-UHFFFAOYSA-N 1-methyl-3,4-dihydro-2h-quinoline-6-carbaldehyde Chemical compound O=CC1=CC=C2N(C)CCCC2=C1 XPXZIZIGEKZVMQ-UHFFFAOYSA-N 0.000 description 4
- CMPOSLJLQIYWIJ-UHFFFAOYSA-N 2-bromo-4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C(Br)=C1 CMPOSLJLQIYWIJ-UHFFFAOYSA-N 0.000 description 4
- ONPPYVIEJPDKTI-UHFFFAOYSA-N 3,5-dichloro-n,n-dimethyl-4-(2-nitroprop-1-enyl)aniline Chemical compound CN(C)C1=CC(Cl)=C(C=C(C)[N+]([O-])=O)C(Cl)=C1 ONPPYVIEJPDKTI-UHFFFAOYSA-N 0.000 description 4
- YJCNUSPWDQIVAI-UHFFFAOYSA-N 3,5-dichloro-n,n-dimethylaniline Chemical compound CN(C)C1=CC(Cl)=CC(Cl)=C1 YJCNUSPWDQIVAI-UHFFFAOYSA-N 0.000 description 4
- ALWOQQKTDGWROG-UHFFFAOYSA-N 3-chloro-n,n-dimethyl-4-(2-nitroprop-1-enyl)aniline Chemical compound CN(C)C1=CC=C(C=C(C)[N+]([O-])=O)C(Cl)=C1 ALWOQQKTDGWROG-UHFFFAOYSA-N 0.000 description 4
- BJHRBKNEZCMBEK-UHFFFAOYSA-N 4-(2-aminopropyl)-3,5-dichloro-n,n-dimethylaniline;dihydrochloride Chemical compound Cl.Cl.CC(N)CC1=C(Cl)C=C(N(C)C)C=C1Cl BJHRBKNEZCMBEK-UHFFFAOYSA-N 0.000 description 4
- UYKVCEFSIRLICW-UHFFFAOYSA-N 4-(2-aminopropyl)-3-bromo-n,n-dimethylaniline;dihydrochloride Chemical compound Cl.Cl.CC(N)CC1=CC=C(N(C)C)C=C1Br UYKVCEFSIRLICW-UHFFFAOYSA-N 0.000 description 4
- VNIAJBAJBCCYOT-UHFFFAOYSA-N 4-(2-aminopropyl)-n,n,3-trimethylaniline;hydron;dichloride Chemical compound Cl.Cl.CC(N)CC1=CC=C(N(C)C)C=C1C VNIAJBAJBCCYOT-UHFFFAOYSA-N 0.000 description 4
- XZWMCPUAUNHGPF-UHFFFAOYSA-N 4-(dimethylamino)-2-methylbenzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C(C)=C1 XZWMCPUAUNHGPF-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- YVBSECQAHGIWNF-UHFFFAOYSA-N N-methyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2N(C)CCCC2=C1 YVBSECQAHGIWNF-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 4
- 239000012259 ether extract Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- CWOMTHDOJCARBY-UHFFFAOYSA-N n,n,3-trimethylaniline Chemical compound CN(C)C1=CC=CC(C)=C1 CWOMTHDOJCARBY-UHFFFAOYSA-N 0.000 description 4
- WWPITPSIWMXDPE-UHFFFAOYSA-N para-chloroamphetamine Chemical compound CC(N)CC1=CC=C(Cl)C=C1 WWPITPSIWMXDPE-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- APFUBRHQRCSLEL-UHFFFAOYSA-N 2,6-dichloro-4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC(Cl)=C(C=O)C(Cl)=C1 APFUBRHQRCSLEL-UHFFFAOYSA-N 0.000 description 3
- XPSKJQZOTXBHIQ-UHFFFAOYSA-N 3-bromo-n,n-dimethyl-4-(2-nitroprop-1-enyl)aniline Chemical compound CN(C)C1=CC=C(C=C(C)[N+]([O-])=O)C(Br)=C1 XPSKJQZOTXBHIQ-UHFFFAOYSA-N 0.000 description 3
- HGJBTCRUCFIRAW-UHFFFAOYSA-N 4-(2-aminopropyl)-3-chloro-n,n-dimethylaniline;dihydrochloride Chemical compound Cl.Cl.CC(N)CC1=CC=C(N(C)C)C=C1Cl HGJBTCRUCFIRAW-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 238000004061 bleaching Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- XSQFAWMDRFSIMY-UHFFFAOYSA-N 2-chloro-4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C(Cl)=C1 XSQFAWMDRFSIMY-UHFFFAOYSA-N 0.000 description 2
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 2
- USEXQPWLCGBYNT-UHFFFAOYSA-N 3-bromo-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(Br)=C1 USEXQPWLCGBYNT-UHFFFAOYSA-N 0.000 description 2
- NWZHZXQLJMBQQL-UHFFFAOYSA-N 4-(2-aminopropyl)-2-bromo-n,n-dimethylaniline;dihydrochloride Chemical compound Cl.Cl.CC(N)CC1=CC=C(N(C)C)C(Br)=C1 NWZHZXQLJMBQQL-UHFFFAOYSA-N 0.000 description 2
- NWQNCALMMPMUFF-UHFFFAOYSA-N 4-(2-aminopropyl)-n,n-dimethylaniline;dihydrochloride Chemical compound Cl.Cl.CC(N)CC1=CC=C(N(C)C)C=C1 NWQNCALMMPMUFF-UHFFFAOYSA-N 0.000 description 2
- GQYQBPYWZHMWGZ-UHFFFAOYSA-N 4-(2-aminopropyl)-n-ethylaniline;dihydrochloride Chemical compound Cl.Cl.CCNC1=CC=C(CC(C)N)C=C1 GQYQBPYWZHMWGZ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- MOMWFXLCFJOAFX-UHFFFAOYSA-N OOOOOOOO Chemical compound OOOOOOOO MOMWFXLCFJOAFX-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002539 anti-aggressive effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZRFJFBXQIARIQB-UHFFFAOYSA-N 1-methyl-6-(2-nitroprop-1-enyl)-3,4-dihydro-2h-quinoline Chemical compound [O-][N+](=O)C(C)=CC1=CC=C2N(C)CCCC2=C1 ZRFJFBXQIARIQB-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 description 1
- FQFJMNOXKPUKOF-UHFFFAOYSA-N 4-(2-amino-2-methylpropyl)-n,n-dimethylaniline;dihydrochloride Chemical compound Cl.Cl.CN(C)C1=CC=C(CC(C)(C)N)C=C1 FQFJMNOXKPUKOF-UHFFFAOYSA-N 0.000 description 1
- HFQMYSHATTXRTC-UHFFFAOYSA-N 4-(2-aminopropyl)-n,n,3-trimethylaniline Chemical compound CC(N)CC1=CC=C(N(C)C)C=C1C HFQMYSHATTXRTC-UHFFFAOYSA-N 0.000 description 1
- FVWYYMBKTLPHFU-UHFFFAOYSA-N CC=1C=C(N)C=CC1C=C(C)[N+](=O)[O-] Chemical compound CC=1C=C(N)C=CC1C=C(C)[N+](=O)[O-] FVWYYMBKTLPHFU-UHFFFAOYSA-N 0.000 description 1
- JEWZSAXQJJIDLE-UHFFFAOYSA-N CN(C1=CC(=C(C=C1)C=C(C)C)Br)C Chemical compound CN(C1=CC(=C(C=C1)C=C(C)C)Br)C JEWZSAXQJJIDLE-UHFFFAOYSA-N 0.000 description 1
- OQAWPECNMXDZRZ-UHFFFAOYSA-N CN1CCCC2=CC(=CC=C12)C(C(C)[N+](=O)[O-])=O Chemical compound CN1CCCC2=CC(=CC=C12)C(C(C)[N+](=O)[O-])=O OQAWPECNMXDZRZ-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 241000412298 Harma Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 241000556720 Manga Species 0.000 description 1
- 101100252165 Mus musculus Rnd2 gene Proteins 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- HFEFMUSTGZNOPY-UHFFFAOYSA-N OOOOOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOOOOO HFEFMUSTGZNOPY-UHFFFAOYSA-N 0.000 description 1
- RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7312002 | 1973-09-04 | ||
| SE7312001A SE382047B (sv) | 1973-09-04 | 1973-09-04 | Forfarande for framstellning av 4-aminoamfetaminderivat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI257674A7 FI257674A7 (cs) | 1975-03-05 |
| FI62281B FI62281B (fi) | 1982-08-31 |
| FI62281C true FI62281C (fi) | 1982-12-10 |
Family
ID=20318423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI2576/74A FI62281C (fi) | 1973-09-04 | 1974-09-03 | Foerfarande foer framstaellning av antidepressivt verksamma 4-minoamfetaminderivat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3996381A (cs) |
| JP (1) | JPS5835177B2 (cs) |
| AT (1) | AT336566B (cs) |
| BE (1) | BE819515A (cs) |
| CA (1) | CA1051436A (cs) |
| CH (2) | CH599106A5 (cs) |
| DE (1) | DE2440734C2 (cs) |
| DK (1) | DK139716B (cs) |
| FI (1) | FI62281C (cs) |
| FR (1) | FR2242079B1 (cs) |
| GB (1) | GB1461667A (cs) |
| HK (1) | HK75778A (cs) |
| IE (1) | IE40514B1 (cs) |
| LU (1) | LU70852A1 (cs) |
| NL (1) | NL7411753A (cs) |
| NO (2) | NO139408C (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059743A1 (en) * | 2000-11-01 | 2005-03-17 | Sention, Inc. | Methods for treating mild cognitive impairment and alzheimer's disease |
| US7619005B2 (en) * | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
| US20030232890A1 (en) * | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
| US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| US20070117869A1 (en) * | 2000-11-01 | 2007-05-24 | Cognition Pharmaceuticals Llc | Methods for treating coginitive impairment and improving cognition |
| TWI291871B (en) * | 2000-11-01 | 2008-01-01 | Cognition Pharmaceuticals Llc | Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117160A (en) * | 1961-07-27 | 1964-01-07 | Pfizer & Co C | Aralkylamines |
| US3496195A (en) * | 1966-05-11 | 1970-02-17 | Chinoin Gyogyszer Es Vegyeszet | D-o-bromo-phenyl-isopropyl-methylpropinylamine and its salts |
-
1974
- 1974-08-14 US US05/497,295 patent/US3996381A/en not_active Expired - Lifetime
- 1974-08-24 DE DE2440734A patent/DE2440734C2/de not_active Expired
- 1974-08-30 AT AT702574A patent/AT336566B/de not_active IP Right Cessation
- 1974-09-03 IE IE1824/74A patent/IE40514B1/xx unknown
- 1974-09-03 CH CH1195874A patent/CH599106A5/xx not_active IP Right Cessation
- 1974-09-03 FI FI2576/74A patent/FI62281C/fi active
- 1974-09-03 JP JP49100618A patent/JPS5835177B2/ja not_active Expired
- 1974-09-03 FR FR7429970A patent/FR2242079B1/fr not_active Expired
- 1974-09-03 DK DK464774AA patent/DK139716B/da not_active IP Right Cessation
- 1974-09-03 CA CA208,356A patent/CA1051436A/en not_active Expired
- 1974-09-03 CH CH1173577A patent/CH603547A5/xx not_active IP Right Cessation
- 1974-09-03 GB GB3849974A patent/GB1461667A/en not_active Expired
- 1974-09-04 BE BE148180A patent/BE819515A/xx not_active IP Right Cessation
- 1974-09-04 LU LU70852A patent/LU70852A1/xx unknown
- 1974-09-04 NO NO743177A patent/NO139408C/no unknown
- 1974-09-04 NL NL7411753A patent/NL7411753A/xx not_active Application Discontinuation
-
1978
- 1978-12-28 HK HK757/78A patent/HK75778A/xx unknown
-
1979
- 1979-05-04 NO NO791507A patent/NO142624C/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK139716B (da) | 1979-04-02 |
| HK75778A (en) | 1979-01-05 |
| AT336566B (de) | 1977-05-10 |
| CH603547A5 (cs) | 1978-08-31 |
| DK464774A (cs) | 1975-05-05 |
| NO791507L (no) | 1975-03-05 |
| FI62281B (fi) | 1982-08-31 |
| CA1051436A (en) | 1979-03-27 |
| CH599106A5 (cs) | 1978-05-12 |
| FR2242079B1 (cs) | 1978-07-21 |
| DE2440734C2 (de) | 1985-01-24 |
| BE819515A (fr) | 1975-03-04 |
| AU7283374A (en) | 1976-03-04 |
| US3996381A (en) | 1976-12-07 |
| LU70852A1 (cs) | 1975-06-11 |
| NO139408B (no) | 1978-11-27 |
| IE40514L (en) | 1975-03-04 |
| NO142624B (no) | 1980-06-09 |
| FI257674A7 (cs) | 1975-03-05 |
| NL7411753A (nl) | 1975-03-06 |
| NO743177L (cs) | 1975-04-01 |
| JPS5835177B2 (ja) | 1983-08-01 |
| DK139716C (cs) | 1979-09-17 |
| GB1461667A (en) | 1977-01-19 |
| JPS5050329A (cs) | 1975-05-06 |
| NO139408C (no) | 1979-03-07 |
| FR2242079A1 (cs) | 1975-03-28 |
| NO142624C (no) | 1980-09-17 |
| DE2440734A1 (de) | 1975-03-13 |
| IE40514B1 (en) | 1979-06-20 |
| ATA702574A (de) | 1976-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8071786B2 (en) | Indole compounds useful as serotonin selective agents | |
| DE69322033T2 (de) | Kondensierte Pyridin Derivate als Hemmer von Effekten freier Radikaler | |
| US20070299079A1 (en) | 4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | |
| DD152935A5 (de) | Substituierte beta-carbolin-3-carbonsaeure-derivate | |
| DE60101323T2 (de) | Tricyclische proteinkinasehemmer | |
| RU2191776C2 (ru) | Эрголиновые производные, способ их получения, фармацевтическая композиция | |
| US5672705A (en) | Imidazo (1,2-A)pyrazine-4-one derivatives/useful as antagonists of AMPA and NMDA receptors | |
| SK12332002A3 (sk) | Deriváty chinolínu ako alfa 2 antagonisty | |
| CN101346375B (zh) | 调节门离子通道用组合物和方法 | |
| FI62281C (fi) | Foerfarande foer framstaellning av antidepressivt verksamma 4-minoamfetaminderivat | |
| US20150196529A1 (en) | Use of flavone and flavanone derivatives in preparation of sedative and hypnotic drugs | |
| DD151754A5 (de) | Pyrazolochinoline,verfahren zu ihrer herstellung,pharmazeutische praeparate enthaltend diese verbindungen,sowie ihre therapeutische verwendung | |
| NO313963B1 (no) | 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater | |
| EP1833830A1 (de) | Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel | |
| CZ9394A3 (en) | 9H-IMIDAZO/1,2-a/BENZIMIDAZOL-3-ACETAMIDO DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS IN WHICH THEY ARE COMPRISED | |
| DE3587556T2 (de) | 2-Substituierte Aminomethyl-1,4-benzodiazepine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen. | |
| JP2807633B2 (ja) | Ｎ−（ピリジニル）−ｉｈ−インドール−１−アミンを含有する強迫疾患治療剤 | |
| WO2008084491A1 (en) | 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands | |
| JPH01265076A (ja) | 医薬品 | |
| WO2007138611A1 (en) | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands | |
| Guan et al. | Synthesis and evaluation of phenyliminoindolin-containing phenylacetamide derivatives with the antidepressant and anticonvulsant effects | |
| HUP9903619A2 (hu) | 5HT2c Antagonistát és D2 antagonistát tartalmazó gyógyszerkészítmény | |
| DE102004063223A1 (de) | Chinolinderivat, dessen Verwendung, Herstellung und dieses enthaltendes Arzneimittel | |
| CN107586281A (zh) | 芳烷杂环类衍生物及其在多靶点抗抑郁症中的应用 | |
| DE602005001434T2 (de) | Arylpiperazinderivate als selektive Liganden für den Dopamin D3 Rezeptor |